alosetron has been researched along with Obesity in 2 studies
alosetron : A pyrido[4,3-b]indole compound having a 5-methyl-1H-imidazol-4-ylmethyl group at the 2-position.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| France, M | 1 |
| Skorich, E | 1 |
| Kadrofske, M | 1 |
| Swain, GM | 1 |
| Galligan, JJ | 1 |
| Camilleri, M | 1 |
1 review available for alosetron and Obesity
| Article | Year |
|---|---|
Pharmacogenomics and serotonergic agents: research observations and potential clinical practice implications.
Topics: Appetite Depressants; Carbolines; Cyclobutanes; Dyspepsia; Gastrointestinal Agents; Genetic Variatio | 2007 |
1 other study available for alosetron and Obesity
| Article | Year |
|---|---|
Sex-related differences in small intestinal transit and serotonin dynamics in high-fat-diet-induced obesity in mice.
Topics: Animals; Carbolines; Diet, High-Fat; Female; Fluoxetine; Gastrointestinal Transit; Intestine, Small; | 2016 |